Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Repurposed fludarabine alleviates type 1 diabetes through the dual effects on dendritic cell activation and β cell ferroptosis

ABSTRACT: Type 1 diabetes (T1D) imposes a substantial burden on patients yet effective therapies to halt disease progression are lacking. Immunomodulatory strategies that suppress autoreactive immune response and preserve pancreatic β cell function are essential for improving long-term therapeutic outcome. Herein, we repurposed fludarabine, a clinically applied drug, in the T1D setting. Fludarabine treatment markedly alleviates inflammatory immune activation and β cell destruction. Moreover, fludarabine induces tolerogenic dendritic cell (DC) phenotype through chemical reprogramming. The protective effect of fludarabine-treated DCs was further corroborated by adoptive transfer experiment. Mechanistically, fludarabine directly binds to STAT1 and disrupts its interaction with the aryl hydrocarbon receptor (AHR), thereby facilitating AHR nuclear translocation. Activated AHR transcriptionally upregulates anti-inflammatory and anti-ferroptotic programs, conferring a tolerogenic DC phenotype and protecting β cells from stress-induced ferroptosis. Collectively, our findings identify fludarabine as a promising immunometabolic therapeutic candidate that restores immune tolerance and enhances β cell resilience, which could be a viable approach against T1D in clinical settings.

ORGANISM(S): Mus musculus

PROVIDER: GSE296740 | GEO | 2026/06/10

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Aryl hydrocarbon receptor activity downstream of IL-10 signaling is required to promote regulatory functions in human dendritic cells [RNA_in_vitro_DC10_iDC_DC10CH]

Project description:Peripheral immune tolerance is a key physiological mechanism sustained by the activity of regulatory cells that impedes immune reaction to self and non-dangerous antigens. Interleukin 10 (IL-10) plays a key immunosuppressive role in this system by inhibiting effector cells and instructing regulatory cells. While the molecular mechanisms and gene expression patterns defining identity and function of T regulatory cells have been deeply studied, the molecular pattern driving tolerogenicity in myeloid antigen presenting cells remain less defined. We have investigated the molecular mechanisms underlying IL-10 tolerogenic activity in human myeloid cells. By performing chromatin and transcriptomic studies in IL-10-induced monocyte-derived DC, we have found that IL-10 imprinted a pattern of accessible enhancers, which were exploited by Aryl Hydrocarbon Receptor (AHR) to promote the expression of a set of core genes. Functional studies demonstrated that AHR activation and core gene expression were necessary for IL-10-mediated induction of tolerogenic functions in in vitro differentiated DC. AHR exerted its role down-stream to IL-10 inducing tolerogenic and repressing inflammatory genes. Analyses of naturally occurring tolerogenic DC from peripheral blood showed that the IL-10-induced AHR module was active also in vivo in healthy conditions. In multiple sclerosis patients, instead, we observed significant alterations in the IL-10-induced AHR module that correlated with functional defects and reduced frequencies of in vitro differentiated and in vivo occurring IL-10-induced tolerogenic DC, respectively. This study unveiled a previously undescribed IL-10-induced molecular mechanism required for establishing tolerogenic functions in human myeloid cells.

2023-03-04 | GSE180761 | GEO

Aryl hydrocarbon receptor activity downstream of IL-10 signaling is required to promote regulatory functions in human dendritic cells [RNA_in_vitro_DC10_MS]

2023-03-04 | GSE180760 | GEO

Aryl hydrocarbon receptor activity downstream of IL-10 signaling is required to promote regulatory functions in human dendritic cells [RNA_ex_vivo_DC10_MS]

2023-03-04 | GSE180755 | GEO

Aryl hydrocarbon receptor activity downstream of IL-10 signaling is required to promote regulatory functions in human dendritic cells [ATAC_in_vitro_DC10_iDC_DC10CH]

2023-03-04 | GSE180754 | GEO

Aryl hydrocarbon receptor activity downstream of IL-10 signaling is required to promote regulatory functions in human dendritic cells [ATAC_ex_vivo_DC10_cDC]

2023-03-04 | GSE180753 | GEO

Gamma-secretase inhibitor plus fludarabine in CLL

2013-09-21 | GSE51044 | GEO

Transposon mutagenesis reveals fludarabine-resistance mechanisms in chronic lymphocytic leukemia

Project description:Purpose:To identify resistance mechanisms for the chemotherapeutic drug fludarabine in chronic lymphocytic leukemia (CLL), as innate and acquired resistance to fludarabine-based chemotherapy represents a major challenge for long-term disease control. Methods: We employed piggyBac transposon-mediated mutagenesis, combined with next-generation sequencing, to identify genes that confer resistance to fludarabine in a human CLL cell line. Results: RNA-seq profiling of fludarabine-resistant cells suggested deregulated MAPK signaling as involved in mediating drug resistance in CLL.

2016-03-31 | GSE75844 | GEO

Fludarabine resistance in Mantle cell lymphoma

Project description:SILAC analysis of fludarabine resistance in human Mino cells.

2015-08-03 | PXD002034 | Pride

Gamma-secretase inhibitor plus fludarabine in CLL

Project description:Combination of GSI with fludarabine has a synergistic antileukemic effect in primary NOTCH1-mutated CLL cells We used microarrays to detail the mechanism of synergy of GSI and fludarabine combination in NOTCH1-mutated CLL cells Global RNA expression in CLL primary cells treated with GSI, fludarabine and the combination at 48 hours of treatment

2013-09-21 | E-GEOD-51044 | biostudies-arrayexpress

Changes in gene expression induced by CDK9 inhibition alone and in combination with fludarabine

Project description:Using a transcriptomics approach we explored the mechanism(s) of synergy observed between CDKI-73 and fludarabine in primary CLL cells. The cytotoxic effects of CDKI-73 were associated with transcriptional inhibition of cdk9 target genes including MCL1 and XIAP. In contrast, fludarabine induced the transcription of these genes, an effect that was reversed by the combination of CDKI-73 and fludarabine. We used microarrays to explore the cytoxic synergy observed in primary CLL cells when we combined a novel CDK9 inhibitor with the purine nucleoside analogue fludarabine

2013-06-25 | GSE48258 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data